Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...